Sickle Cell Disease: In a landmark advancement for Indian healthcare, doctors at Fortis Memorial Research Institute (FMRI), Gurugram, have reported exceptional success in curing children suffering from Sickle Cell Disease (SCD) through Bone Marrow (stem cell) transplantation. This breakthrough places India mong the leading nations achieving world-class outcomes in advanced paediatric transplants.
Sickle Cell Disease: About the Study
The decade-long study, published in the international journal Haemoglobin, analysed 100 paediatric cases treated between 2015 and 2024.
- Overall survival rate:87%
- Matched sibling donor (MSD) transplants:96% success
- Half-matched (haploidentical) family donor transplants:78% success
These results represent one of the best-reported global outcomes for Sickle Cell Disease treatment, marking a major step forward for developing nations in managing this life-threatening disorder.
Sickle Cell Disease: Understanding Sickle Cell Disease
Sickle Cell Disease (SCD) is an inherited blood disorder affecting millions worldwide—especially in India and sub-Saharan Africa, which together account for nearly half of global cases.
The disease causes severe anemia, pain crises, stroke, and organ damage, significantly reducing life expectancy.
Until now, treatment primarily involved symptom control through medications and blood transfusions.
However, stem cell transplantation (Bone Marrow Transplant, BMT) offers a permanent cure by replacing the defective bone marrow with healthy stem cells from a compatible donor.
Sickle Cell Disease: Expert Insights
“A Ray of Hope for Families” — Dr. Swati Bhayana
“This is a ray of hope for families living with Sickle Cell Disease,” said Dr. Swati Bhayana, Lead Author of the study and Consultant, Paediatric Haematology, Oncology, and Bone Marrow Transplant, Fortis Gurugram.
“Our research shows that children in developing countries like India and Africa can achieve survival rates comparable to the best centres globally when given timely access to advanced care.”
Dr. Bhayana emphasized that early diagnosis and timely transplant are critical for long-term survival, particularly before complications like stroke or organ damage develop.
“Every Child Deserves a Normal Life” — Dr. Vikas Dua
Dr. Vikas Dua, Principal Consultant & Head, Paediatric Haematology, Oncology and Bone Marrow Transplant, Fortis Gurugram, added:
“Many of these children had been living with pain, repeated hospitalizations, and dependence on transfusions. Today, they are leading healthy, active lives.
This milestone reinforces our belief that every child deserves a chance at a normal life and that early intervention is the key to success.”
Sickle Cell Disease: Advances in Haploidentical Transplants
The study reported significant progress in haploidentical (half-matched) transplants, which allow the use of parental donors when a full sibling match is unavailable. The adoption of reduced-toxicity conditioning and post-transplant cyclophosphamide (PTCy) protocols has lowered complication rates, making the procedure safer and expanding accessibility.
“Innovation for the Developing World” — Dr. Rahul Bhargava
Dr. Rahul Bhargava, Principal Director, Institute of Blood Disorders and Bone Marrow Transplant, Fortis Gurugram, highlighted the broader implications:
“India and Africa together carry nearly half the world’s burden of Sickle Cell Disease.
By developing cost-effective, safe, and scalable transplant protocols, we are proving that cutting-edge innovation doesn’t have to be limited to the developed world.”
“Collaboration and Awareness Are Key” — Dr. Sohini Chakraborty
Dr. Sohini Chakraborty, Senior Consultant, Paediatric Haematology, Oncology, and Bone Marrow Transplant, Fortis Gurugram, said:
“The findings underscore the importance of awareness, collaboration, and early diagnosis.
With improved donor registries, infection control, and stronger post-transplant care, the cure for Sickle Cell Disease can become a global reality.”
“Innovation Must Serve Humanity” — Mr. Yashpal Rawat
Mr. Yashpal Rawat, VP & Facility Director, Fortis Gurugram, added:
“At Fortis, we believe that innovation must serve humanity.
This breakthrough reflects our mission to combine world-class technology with compassion, making lifesaving treatments available and affordable for families in India, Africa, and beyond.”
Sickle Cell Disease: Summary of the Study
“Encouraging Outcomes of Hematopoietic Stem Cell Transplantation (HSCT) in Pediatric Sickle Cell Disease: A Decade-Long Experience from the Devloping World.”
Background and Significance
- Sickle Cell Disease (SCD) affects over 300,000 newborns annually worldwide.
- It causes significant morbidity and reduced life expectancy.
- HSCT remains the only curative treatment, but challenges include:
- Donor availability
- Socio-economic barriers
- Transplant complications such as graft-versus-host disease (GVHD)
- Limited data exist from non-Western countries, making this study a crucial contribution.
Study Design and Patient Demographics
- Type:Retrospective cohort study
- Sample size:100 pediatric SCD patients (2015–2024)
- Evaluated:92 patients
- 55 HLA-identical sibling transplants
- 37 haploidentical transplants
- Median follow-up:6 months
- Median age:5 years
Transplant Outcomes
- Overall survival (OS):9%
- Matched sibling donor (MSD):4%
- Haploidentical:3%
- Event-free survival (EFS):77%
- Stable engraftment:2% of patients
- Improved outcomes observed after adopting reduced-toxicity regimens.
Complications and GVHD
- Acute GVHD incidence:26%
- Chronic GVHD (2-year):4%
- Viral reactivations:18 patients (mainly CMV)
- Other side effects included mucositisand endothelial complications; some required parenteral nutrition.
Discussion and Implications
The findings confirm the safety and efficacy of HSCT for paediatric SCD patients, particularly with matched sibling donors.
They emphasize the importance of early transplantation, improved donor registries, and post-transplant care to achieve better survival outcomes.
This research adds valuable data from low- and middle-income countries, paving the way for broader access to curative therapies.
Conclusion
The FMRI team’s decade-long effort has positioned India at the forefront of global pediatric transplant success.
With ongoing research, collaboration, and awareness, the dream of curing Sickle Cell Disease for every child—regardless of geography or income—is becoming a realistic goal.
About Fortis Healthcare Limited
Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics, and day care specialty facilities. Currently, the company operates 33 healthcare facilities (including JVs and O&M facilities) across 11 states. The Company’s network comprises over 5,700 operational beds (including O&M beds) and 400 diagnostics labs.
For more information, please contact:
| Organization | Department / Agency | Contact Person | Phone | |
|---|---|---|---|---|
| Fortis Healthcare Ltd. | AGM – Corporate Communications | Rishu Singh | +91 99588 91501 | rishu.singh@fortishealthcare.com |
| Adfactors PR | — | Devanshi Sharma | +91 90580 76191 | devanshi.sharma@adfactorspr.com |
| Adfactors PR | — | Drishti Gupta | +91 84482 44139 | drishti.gupta@adfactorspr.com |
Fortis Healthcare Ltd.
Head – Corporate Communications & PR
Ajey Maharaj: +919871798573
